Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2026)

Contineum Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 139.85% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 139.85% YoY), while the FY2025 annual figure was $6.4 million, down 4.83% from the prior year.
• Accumulated Expenses was $2.9 million for Q1 2026 at Contineum Therapeutics, down from $6.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $6.7 million in Q4 2024 to a low of $959000.0 in Q1 2024.
• Historically, Accumulated Expenses has averaged $3.1 million across 4 years, with a median of $2.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses retreated 4.83% in 2025, then surged 139.85% in 2026.
• A 4-year view of Accumulated Expenses shows it stood at $4.4 million in 2023, then jumped by 53.04% to $6.7 million in 2024, then declined by 4.83% to $6.4 million in 2025, then plunged by 55.24% to $2.9 million in 2026.
• The last three Accumulated Expenses figures came in at $2.9 million (Q1 2026), $6.4 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.